Skip to content

Opinions of Company Representatives About Neuromodulation

Opinions of Company Representatives About Neuromodulation for Pain: an Online Survey

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05013827
Enrollment
39
Registered
2021-08-19
Start date
2021-09-02
Completion date
2021-09-09
Last updated
2022-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuromodulation, Pain, Survey

Brief summary

The goal of this online survey is to gain further insight in the goals, expectations and definition of success for neuromodulation for pain, according to neuromodulation company representatives.

Interventions

Company representatives are questioned about three aspects: 1) goals in treating patients with neuromodulation for pain, 2) factors that respondents expect to change according to neuromodulation for pain and 3) their definition of success of neuromodulation for pain.

Sponsors

Moens Maarten
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

\- Male and female adults who are involved in the management of chronic pain and more specifically in neuromodulation for pain as company representatives will be eligible to complete the survey.

Exclusion criteria

\- Not a company representative.

Design outcomes

Primary

MeasureTime frameDescription
Company representatives definition of success of neuromodulation for pain, evaluated with a self-constructed question.Cross-sectional evaluation during 2nd Joint Congress of the INS European Chapters (e-INS 2021) in Paris in September.Company representatives their definition of success of neuromodulation for pain.
Goals of company representatives, evaluated with a self-constructed question.Cross-sectional evaluation during 2nd Joint Congress of the INS European Chapters (e-INS 2021) in Paris in September.Goals of company representatives to treat patients with neuromodulation for pain.
Company representatives expectations, evaluated with a self-constructed question.Cross-sectional evaluation during 2nd Joint Congress of the INS European Chapters (e-INS 2021) in Paris in September.Factors that respondents expect to change according to neuromodulation for pain.

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026